Metformin in type 1 diabetes

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 8, 2017, Pages 567-569

  Standl, Eberhard ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

ADD ON THERAPY; ARTERIAL WALL THICKNESS; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; DRUG USE; ESTIMATED GLOMERULAR FILTRATION RATE; GLUCONEOGENESIS; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY FUNCTION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 85020400721     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30216-4     Document Type: Note

References (9)

1. Petrie, JR, Chaturvedi, N, Ford, I, et al., REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol, 2017 published online June 11 http://dx.doi.org/10.1016/S2213-8587(17)30194-8.
2. The National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17, 2015, UK National Institute for Health and Care Excellence https://www.nice.org.uk/guidance/ng17?unlid=43059219201639184149 (accessed June 1, 2017).
3. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 40:suppl 1 (2017), S1–S135.
4. Vella, S, Buetow, L, Royle, P, Livingstone, S, Colhoun, H, Petrie, JR, The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53 (2010), 809–820.
5. Libman, IM, Miller, KM, DiMeglio, LA, et al., T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 314 (2015), 2241–2250.
6. Foretz, M, Guigas, B, Bertrand, L, Pollak, M, Viollet, B, Metformin: from mechanisms of action to therapies. Cell Metab 20 (2014), 953–966.
7. Song, R, Mechanism of metformin: a tale of two sites. Diabetes Care 39 (2016), 187–189.
8. Buse, JB, DeFronzo, RA, Rosenstock, J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39 (2016), 198–205.
9. Mulherin, AJ, Oh, AH, Kim, H, Grieco, A, Lauffer, LM, Brubaker, PL, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152 (2011), 4610–4619.